An open-label phase I dose-finding study of APR-246 in hematological malignancies

Blood Cancer Journal

Volumn 6, Issue 7, 2016, Pages

  Deneberg, S ^a   Cherif, H ^b   Lazarevic, V ^c   Andersson, P O ^d   von Euler, M ^e   Juliusson, G ^c   Lehmann, S ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Aprea AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2-HYDROXYMETHYL-2-METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN-3-ONE; ANTINEOPLASTIC AGENT; QUINUCLIDINE DERIVATIVE;

ADULT; AGED; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINUCLIDINES; TREATMENT OUTCOME;

EID: 85016437418     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2016.60     Document Type: Letter

References (5)

1. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594–604.
2. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. p53 as a target for the treatment of cancer. Cancer Treat Rev 2014; 40: 1153–1160.
3. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U et al. Targeting p53 in vivo: afirst-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633–3639.
4. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376–388.
5. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282–288.